Atlas Trials

Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy

Clinical trial NCT05560308 · UNKNOWN

Trial details

NCT number
NCT05560308
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
Start date
2022-09-30
Primary completion
2024-08-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.